Syngene International Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts more than Nifty Smallcap 250 and 8.9 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International reported consolidated revenue of Rs 37,387 million for FY2026, up 2.6% from Rs 36,424 million in FY2025. However, profit after tax (PAT) declined significantly to Rs 3,167 million from Rs 4,962 million in the previous year, a fall of approximately 36%. EBITDA margin compressed from about 30.4% to 24.3% year-on-year. The company recorded exceptional items including Rs 462 million (net) related to new labour code implementation and Rs 304 million in employee termination benefits. Foreign exchange losses of Rs 609 million also impacted results compared to just Rs 19 million in FY2025. The Board recommended a final dividend of Rs 1.25 per share (same as last year) and approved appointment of S.R. Batliboi & Associates LLP as new statutory auditors for 5 years. The auditors issued unqualified opinions with no concerns.
The sharp PAT decline and EBITDA margin compression despite modest revenue growth is a negative signal for shareholders. Investors will focus on whether the margin pressure from higher employee costs, FX losses, and exceptional items is temporary or structural. The unchanged dividend provides some support.